Publication | Closed Access
A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC)
192
Citations
0
References
2001
Year
Phase Ii TrialMedicinePharmacologyCancer GrowthPathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung CancerPlatinum-based Chemotherapy
No additional data available for this publication yet. Check back later!